Molecular evaluation of ablative therapy of Barrett's oesophagus

Journal of Pathology

Volumn 205, Issue 1, 2005, Pages 57-64

  Hage, Mariska ^a   Siersema, Peter D ^a   Vissers, Kees J ^a   Steyerberg, Ewout W ^a   Haringsma, Jelle ^a   Kuipers, Ernst J ^a   van Dekken, Herman ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Ablation; Argon plasma coagulation; Barrett's oesophagus; Dysplasia; Hyperdiploidy; Ki67; p53; Photodynamic therapy

Indexed keywords

AMINOLEVULINIC ACID; DNA; KI 67 ANTIGEN; PROTEIN P53;

ADULT; AGED; ARGON PLASMA COAGULATION; ARTICLE; BARRETT ESOPHAGUS; BIOPSY; CELL CYCLE PHASE; CELL PROLIFERATION; CHROMOSOME 1; CHROMOSOME ABERRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DYSPLASIA; ESOPHAGOSCOPY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTERPHASE; INTESTINE METAPLASIA; MALE; MOLECULAR BIOLOGY; PHOTODYNAMIC THERAPY; PLOIDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT DISEASE;

ADULT; AGED; BARRETT ESOPHAGUS; CHROMOSOME ABERRATIONS; COMBINED MODALITY THERAPY; DNA, NEOPLASM; ESOPHAGEAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KI-67 ANTIGEN; LASER COAGULATION; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM, RESIDUAL; PHOTOCHEMOTHERAPY; PLOIDIES; PRECANCEROUS CONDITIONS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 11144311304     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1685     Document Type: Article

References (33)

1. Botterweck AA, Schouten LJ, Volovics A, Dorant E, van Den Brandt PA. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 2000; 29: 645-654.
2. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83: 2049-2053.
3. Hage M, Siersema PD, van Dekken H, Steyerberg E, Dees J, Kuipers EJ. Oesophageal cancer incidence and mortality in patients with long-segment Barrett's oesophagus after a mean follow-up of 12.7 years. Scand J Gastroenterol (in press).
4. Hameeteman WGN, Tytgat NJ, Houthoff HJ, Van den Tweel JC. Barrett's esophagus: development of dysplasia. and adenocarcinoma. Gastroenterology 1989; 96: 1249-1256.
5. Van Laethem J-L, Cremer M, Perry MO, Delhaye M, Devière J. Eradication of Barrett's mucosa with argon plasma coagulation and acid suppression: immediate and mid term results. Gut 1998; 43: 747-751.
6. Mork H, Barth T, Kreipe HH, et al. Reconstitution of squamous epithelium in Barrett's esophagus with endoscopic argon plasma coagulation: a prospective study. Scand J Gastroenterol 1998; 33 1130-1134.
7. Pereira-Lima JC, Busnello JV, Saul C, et al. High power setting argon plasma coagulation for the eradication of Barrett's esophagus. Am J Gastroenterol 2000; 95: 1661-1668.
8. Morris CD, Byrne JP, Armstrong GRA, Attwood SE. Prevention of the neoplastic progression of Barrett's oesophagus by endoscopic argon beam plasma ablation. Br J Surg 2001; 88: 1357-1362.
9. Basu KK, Pick B, Bale R, West KP, de Caestecker JS. Efficacy and one year follow up of argon plasma coagulation therapy for ablation of Barrett's esophagus: factors determining persistence and recurrence of Barrett's esophagus. Gut 2002; 51: 776-780.
10. Barr H, Shepherd NA, Dix A, Roberts DJH, Tan WC, Krasner N. Eradication of high-grade dysplasia in columnar-lined (Barrett's) esophagus by photodynamic therapy with endogenously generated protoporphyrin IX. Lancet 1996; 348: 584-585.
11. Overholt BF, Panjehpour M, Halberg DL Photodynamic therapy for Barrett's esophagus with dysplasia and/or early stage carcinoma: long-term results. Gastrointest Endosc 2003; 58: 183-188.
12. Gossner L, Stolte M, Sroka R, et al. Photodynamic ablation of high-grade dysplasia and early cancer in Barrett's esophagus by means of 5-aminolevulmic acid. Gastroenterology 1998; 114: 448-455.
13. Ackroyd R, Brown NJ, Davis MF, et al. Photodynamic therapy for dysplastic Barrett's esophagus: a prospective, double blind, randomised, placebo controlled trial. Gut 2000; 47: 612-617.
14. Hage M, Siersema PD, van Dekken H, et al. 5-Aminolevulenic acid photodynamic therapy versus argon plasma coagulation for ablation of Barrett's esophagus: a randomized trial. Gut 2004; 53: 785-790.
15. Gray MR, Hall PA, Nash J, Ansari B, Lane DP, Kingsnorth AN. Epithelial proliferation in Barrett's esophagus by proliferating cell nuclear antigen immunolocalization. Gastroenterology 1992; 103 1769-1776.
16. Krishnadath KK, Tilanus HW, van Blankensteyn M, et al. Accumulation of genetic abnormalities during neoplastic progression in Barrett's esopahgus. Cancer Res 1995; 55: 1971-1976.
17. Reid BJ, Sanchez CA, Blount PL, Levine DS. Barrett's esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterology 1993; 105: 119-129.
18. Menke-Pluymers MBE, Mulder AH, Hop WCJ, van Blankenstein M, Tilanus HW. Dysplasia and aneuploidy as markers of malignant degeneration in Barrett's esophagus. Gut 1994; 35: 1348-1351.
19. Galipeau PC, Cowan DS, Sanchez CA, et al. 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. Proc Natl Acad Sci USA 1996; 93: 7081-7084.
20. Krishnadath KK, Tilanus HW, van Blankenstein M, Bosman FT, Mulder AH. Accumulation of p53 protein in normal, dysplastic and neoplastic Barrett's esophagus. J Pathol 1995; 175: 175-180.
21. Ramel S, Reid BJ, Sanchez CA, et al. Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry. Gastroenterology 1992; 102: 1220-1228.
22. Reid BJ, Prevo LJ, Galipeau PC, et al. Predictors of progression in Barrett's esophagus II: base line 17p (p53) loss of heterozygosity identifies a subset of patients at increased risk for neoplastic progression. Am J Gastroenterol 2001; 96: 2839-2848.
23. Vissers KJ, Riegman PH, Alers JC, Tilanus HW, van Dekken H. Involvement of cancer-activating genes on chromosome 7 and 8 in esophageal (Barrett's) and gastric cardia adenocarcinoma. Anticancer Res 2001; 21: 3813-3820.
24. Alers JC, van Dekken H. Interphase cytogenetic analysis of solid tumors by non-isotopic DNA in situ hybridization. Prog Histochem Cytochem 1996; 31: 1-33.
25. Van Dekken H, Krijtenburg PJ, Alers JC. DNA in situ hybridization (interphase cytogenetics) versus comparative genomic hybridization (CGH) in human cancer: detection of numerical and structural chromosome aberrations. Acta Histochem 2000; 102: 85-94.
26. Spechler SJ. Clinical practice. Barrett's esophagus. N Engl J Med 2002; 346: 836-842.
27. Haggitt RC. Barrett's esophagus, dysplasia and adenocarcinoma. Hum Pathol 1994; 25: 982-993.
28. Sharma P. An update on strategies for eradication of Barrett's mucosa. Am J Med 2001; 111(Suppl 8A): 147S-152S.
29. Van Laethem JL, Peny MO, Salmon I, Cremer M, Deviere J. Intramucosal adenocarcinoma arising under squamous re-epitheliasation of Barrett's esophagus. Gut 2000; 46: 574-575.
30. Shand A, Dallal H, Palmer K, Ghosh S, MacIntyre M. Adenocarcinoma arising in columnar lined esophagus following treatment with argon plasma coagulation. Gut 2001; 48: 580-581.
31. Barrett MT, Sanchez CA, Prevo U, et al. Evolution of neoplastic cell lineages in Barrett's esophagus. Nature Genet 1999; 22: 106-109.
32. Krishnadath KK, Wang KK, Taniguchi K, et al. Persistent genetic abnormalities in Barrett's esophagus after photodynamic therapy. Gastroenterology 2000; 119: 624-630.
33. Weston AP, Banerjee SK, Sharma P, Tran TM, Richards R, Cherian R. P53 protein overexpression in low-grade (LGD) Barrett's esophagus: immunohistochemical marker predictive of progression. Am J Gastroenterol 2001; 96: 1355-1362.